Adverse drug reaction (ADR) detection is a primary regulatory and patient-safety priority for life sciences and health systems. Traditional pharmacovigilance methods often depend on delayed signal detection from siloed data sources and require extensive manual evidence collection. This legacy approach is time-consuming, increases the risk of patient harm, and creates significant regulatory friction. For solution […]